| Budget Amount *help |
¥17,290,000 (Direct Cost: ¥13,300,000、Indirect Cost: ¥3,990,000)
Fiscal Year 2021: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2020: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2019: ¥5,720,000 (Direct Cost: ¥4,400,000、Indirect Cost: ¥1,320,000)
Fiscal Year 2018: ¥5,850,000 (Direct Cost: ¥4,500,000、Indirect Cost: ¥1,350,000)
Fiscal Year 2017: ¥3,640,000 (Direct Cost: ¥2,800,000、Indirect Cost: ¥840,000)
|
|---|
| Outline of Final Research Achievements |
Oral administration of Cistanche tubulosa extract (CT extract) improved motor function and muscle mass in chronic phase of spinal cord injured mice. Oral administration of CT extract also improved walking ability of cast-immobilization-evoked muscle atrophy mice. Acteoside, an active compound in CT extract, transferred to the skeletal muscle and the central nervous system after oral administration of CT extract. When acteoside stimulated skeletal muscle, PKM2 was secreted from skeletal muscles as a myokine. PKM2 traveled to the brain and stimulated VCP on neurons, resulting axonal extension. On the other hand, acteoside also directly activated axonal extension via Akt and MEK in the brain. In a clinical study, locomotive syndrome subjects showed improved performance in walking by CT extract intake.
|
